Researchers examined PET scans from 270 cognitively healthy adults ages 62 to 90 over five years and found that rising anxious-depressive symptoms were linked to higher amyloid-beta protein levels in the brain. The findings in The American Journal of Psychiatry suggest that anxiety symptoms may be an early indicator of preclinical Alzheimer's, said lead author Nancy Donovan.
Positive predictors of progression-free survival in lung cancer patients taking gemcitabine plus cisplatin are younger age and higher body mass index, researchers wrote in Thoracic Cancer. Response to initial therapy as well as higher BMI were predictive of overall survival.
A study in JAMA Neurology found Rituxan, or rituximab, was more effective and less likely to be discontinued than other medications in treatment-naïve patients with relapsing-remitting multiple sclerosis.
The FDA accepted for review Eisai subsidiary Morphotek's investigational new drug application for MORAb-202, which combines farletuzumab with eribulin to treat patients with solid tumors that express folate receptor alpha.
The FDA granted Boston Scientific approval for its Spectra WaveWriter Spinal Cord Stimulator System, which is intended to treat chronic pain using paresthesia-based therapy by producing a light, tingling sensation, and subperception therapy, which produces no sensation. The system provides relief of pain by delivering low pulses of electricity to the spinal cord.
The Center to Advance Palliative Care and the Gary and Mary West Health Institute created training courses and resources health care practitioners can use to support caregivers of dementia patients. Experts said adopting best practices in caregiver support is a win-win for patients, caregivers and the health system.
The Medicare Payment Advisory Commission voted 14-2 to recommend the elimination of the Merit-based Incentive Payment System, with MedPAC policy analysts saying the system is too burdensome and complex for doctors and won't encourage higher-value care. MedPAC proposed replacing MIPS with a voluntary program, under which 2% of payments to clinicians would be withheld unless they agree to join an advanced payment model or choose to be evaluated as part of a larger group based on population-level quality, value and patient experience.
The House's Bipartisan Heroin Task Force has drafted more than a dozen bills intended to address prescription and illegal opioid abuse, including bills that would mandate prescriber education and licensing, electronic-only prescribing of prescriptions for controlled substances, and expanded access to medication-assisted treatment for certain populations, co-chair Tom MacArthur, R-N.J., said.
IBM Watson Health General Manager Deborah DiSanzo says IBM's artificial intelligence is already helping health care teams manage care for some 147,000 high-need patients. Pfizer and IBM Watson Health have worked together on immuno-oncology drug research, hospitals have used the platform to help guide cancer treatment decisions and IBM Watson's Clinical Trial Matching system is streamlining recruitment and enrollment for clinical trials, DiSanzo says.
The Journal of Nuclear Medicine Technology (JNMT) has been selected by Clarivate Analytics for inclusion in its Emerging Sources Citation Index. This coverage begins with 2017. Indexing in the ESCI should improve JNMT's visibility, and it provides a mark of quality -- both of which are good for authors. Read about it.
Through concise, straightforward explanations and supporting graphics that bring abstract concepts to life, Basic Science of Nuclear Medicine -- the Bare Bone Essentials is an ideal tool for anyone looking for an introduction to the fundamentals of the physics and technologies of modern-day nuclear medicine. Order your copy today!
The reasonable man adapts himself to the world: the unreasonable one persists in trying to adapt the world to himself. Therefore all progress depends on the unreasonable man.
George Bernard Shaw, playwright
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at email@example.com.